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Abstract
Background: The DAMOCLES project established a widely used Data Monitoring Committee (DMC) Charter for
randomised controlled trials (RCTs). Typically, within the UK, the DMC is advisory and recommends to another
executive body; the Trial Steering Committee (TSC). Despite the executive role of the TSC, the CONSORT Statement
does not explicitly require reporting of TSC activity, although is included as an example of good reporting. A lack of
guidance on TSC reporting can impact transparency of trial oversight, ultimately leading to a misunderstanding
regarding role and, subsequently, further variation in practice. This review aimed to establish reporting practice of
TSC involvement in RCTs, and thus make recommendations for reporting.
Methods: A cohort examination identifying reporting practice was undertaken. The cohort comprised RCTs
published in three leading medical journals (the British Medical Journal, The Lancet and the New England Journal of
Medicine) within 6 months in 2012 and the full NIHR HTA Monograph series. Details of TSC constitution and impact
were extracted from main publications and published supplements.
Results: Of 415 publications, 264 were eligible. These were typical in terms of trial design. Variations in reporting
between journals and monographs was notable. TSC presence was identified in approximately half of trials (n = 144),
of which 109 worked alongside a DMC. No publications justified not convening a TSC. When reported, the
role of the committee and examples of impact in design, conduct and analysis were summarised.
Conclusions: We present the first review of reporting TSC activity in the published academic literature. An
absence of reporting standards with regards to TSC constitution, activity and impact on trial conduct was
identified which can influence transparency of reporting trial oversight. Consistent reporting is vital for the
benefits and impact of the TSC role to be understood to support adoption of this oversight structure and
reduce global variations in practice.
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Background
The DAMOCLES project [1] established a Data Monitoring
Committee Charter [2] which has been widely used for
randomised controlled trials since 2005. As established
within DAMOCLES, the Data Monitoring Committee
(DMC) is typically advisory and makes recommendations
to another executive body; considered the Trial Steering
Committee (TSC). Currently however, no evidence-based
Charter exists for TSCs to establish their role and function-
ality in RCTs.
The MRC Guidelines for Good Clinical Practice
(1998) defined a three-committee oversight structure:
the day-to-day Trial Management Group, the DMC
and the executive TSC [3]. This document provided
guidance and a suggested terms of reference for TSCs
which has been widely adopted within the UK [4].
However, a need for redevelopment and expansion of
these guidelines has been identified [4, 5]. This may
have led to these guidelines recently being withdrawn,
and subsequently revised, with limited changes mainly
concerning responsibilities to funder. The need for
the development of expanded universal guidelines re-
mains [3, 6].
Both DAMOCLES [1] and the Consolidated Standards
of Reporting Trials (CONSORT) Statement [7], an
evidence-based minimum set of recommendations for
reporting randomised trials, recommend that trial
reports should include information about interim ana-
lyses and the data monitoring process. The purpose of
CONSORT is to facilitate the complete and transparent
reporting of trials and, as such, has been widely adopted
by journals to aid critical appraisal and interpretation.
However, there is an absence of content focussing on
the clinical trial oversight structure and responsibilities
for decision-making. While reporting of DMC activity is
included within CONSORT as part of reporting interim
analyses, and DAMOCLES suggests reporting DMC
membership, the reporting of TSC activities is not
covered.
The objective of this cohort examination was to estab-
lish current practice of reporting of TSC involvement in
RCTs, to recommend reporting standards for TSC activ-
ity and to identify impact on trial conduct.
Methods
Search strategy
EJC searched publications within a 6-month period (1
July 2012 to 31 December 2012) from four sources.
Three top general medical journals (the British Medical
Journal (BMJ), The Lancet (Lancet) and the New England
Journal of Medicine (NEJM)) and within the full UK
National Institute for Health Research Health Technology
Assessment (NIHR HTA) Monograph series. Journals
were selected that are known for endorsing high standards
of reporting when publishing RCTs. The NIHR HTA
Monograph series (HTA), a peer-reviewed, open-access
journal that publishes full details of a single study funded
by the NIHR HTA funding stream. NIHR HTA is a major
UK funding body which supports policy-makers such as
the National Institute for Health and Care Excellence, the
National Screening Committee and the Department of
Health [8]. The full NIHR HTA Monograph series
was searched as opposed to those published within
the set timeframe because this series has a suggested
word count of 50,000 and so enables more details of
the work to be included when compared to a typical
peer-reviewed journal and so were considered more
likely to provide a comprehensive description of TSC remit
and function. Therefore, when summarising examples of
reporting, results from journals and monographs are
reported separately.
Published RCTs were identified by searching of titles,
abstracts and keywords of primary research papers
published within the timeframe using the search term
random*. When eligibility was unclear a second reviewer
(CG) was consulted.
Inclusion criteria
We included all RCTs publishing main trial results.
Articles presenting results of: secondary analyses; pre-
liminary analyses; and additional reports of published
RCTs; for example, results of long-term follow-up,
were excluded.
Data extraction and analysis
A Data Extraction Form was designed and piloted by
EJC and CG. Data was extracted from all published
materials (main trial report and supplementary material
when applicable). EJC extracted data on trial design, trial
stopping and oversight committee reporting (see Table 1)
and entered into an MS Access database. BA independ-
ently extracted data from a random 10%, stratified by
TSC reporting and source.
Quantitative items were analysed using descriptive
statistics. Standard statistical software was used throughout
(Statistical Analysis Software (SAS 9.1.3; SAS Institute Inc.,
Cary, NC, USA)). Text extracts from articles were examined
using NVivo qualitative data analysis software (QSR Inter-
national Pty Ltd. Version 10, 2012). EJC and CG identified
themes within text items which were used to contextualise
and illuminate quantitative results. Extracts are denoted by
(…) and (words) denoted the addition of words or replaced
words to aid understanding. Each paper was mapped to a
unique project identification number; details of this mapping
are given in Additional file 1: Table S1. Due to differences in
focus of paper between journal manuscripts and the mono-
graph series, results are presented split by source and, where
applicable, split into sections appropriate for the content.
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Results
Eligible cohort and demographics
Journals were searched in May 2013. The search
returned 415 hits, of which 264 (63.6%) were eligible
(127 HTA; 16 BMJ; 66 Lancet; 55 NEJM). Figure 1 pro-
vides further details. Trial funders were geographically
distributed with the majority being of UK (n = 161,
61.0%) or USA (n = 50, 18.9%) origin. Typically trials
were parallel (n = 233, 88.3%), two-armed, (n = 185,
70.1%) with a pharmaceutical intervention (n = 132,
50.0%) and blinded (n = 162, 61.4%). Patients were indi-
vidually randomised (n = 237, 90.5%) within the second-
ary and/or tertiary setting (n = 128, 48.5%). Other design
features and characteristics, overall and split by source,
are summarised in Table 2.
Variations in published material
Due to variations in publishing requirements, differences
were anticipated between monographs and journals.
However, there were clear differences between sources,
Key journals were restricted by word count though sup-
plements were often published. While all three journals
encouraged protocol and supplementary appendices, this
appeared to be endorsed by the NEJM only. Further de-
tails are provided in Table 3.
Trial oversight committees
Table 4 describes level of TSC and DMC reporting split
by publication source.
Publications reporting neither a TSC nor DMC (71/264,
26.9%) varied by source from 7% (NEJM, 4/55) to 63%
(BMJ, 10/16). Only NEJM and HTA publications justified
no DMC. NEJM publications justifying no DMC (n = 2)
gave reason in the published protocol as a supplement
stating that the DMC was not applicable (NEJM16) and:
‘A data monitoring committee for efficacy is not
required for this study. Data safety monitoring will be
conducted on an ongoing basis as detailed in the
Safety Review Plan’. (NEJM44)
HTA publications justifying not having a DMC (n =
3) gave reasons: the trial examined routine therapies
(HTA67); no interim analyses were planned (HTA83)
Table 1 Data Extraction Form
The following details were extracted from eligible articles:
Section 1: Trial details
1.1. Title
1.2. Authors
1.3. Journal
1.4. Funding body
1.5. Year of publication (for HTA series only)
1.6. Rationale of trial
Section 2: Trial design
2.1. Recruitment setting, e.g. primary
2.2. Type of trial, e.g. parallel
2.3. Number of trial arms
2.4. Number of primary outcomes
2.5. Type of primary outcome, e.g. subjective
2.6. Unit of randomisation
2.7. Blinding
(i) Level of blinding
(ii)Reasons provided for non-blinding or level of blinding
Section 3: Sample size
3.1. What was the estimated sample size?
3.2. Was the estimated sample size obtained?
Section 4: Trial stopping
4.1. Did the trial stop early? If yes, give details of why and how this
decision was made
Section 5: Oversight committee reporting
5.1. If TSC reported
(i) Are the TSC members listed at the end of the paper?
a. Name of committee
b. Number of members
c. Number of voting members
d. Chair indicated
e. Details regarding the number of members by role and by
voting rights if applicable
(ii) Is the TSC discussed in the main body of the paper? If yes, give
details
5.2. If DMC reported
(i) Are the DMC members listed at the end of the paper?
a. Name of committee
b. Number of members
c. Number of voting members
d. Chair indicated
e. Details regarding the number of members by role and by
voting rights if applicable
Table 1 Data Extraction Form (Continued)
The following details were extracted from eligible articles:
(ii) Is the DMC discussed in the main body of the paper? If yes,
give details
5.3. If applicable, has the absence of committees been justified? If yes,
give details
DMC Data Management Committee, HTA Health Technology Assessment
Monograph series, TSC Trial Steering Committee
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and the trial did not involve a medicinal product
(HTA109).
Of the 120 trials not explicitly reporting use of a TSC,
none justified its absence.
Aside from trials with cellular or gene therapy inter-
ventions of which there were few, TSCs were consist-
ently reported regardless of intervention type, from 48%
of psychological or behavioural intervention trials (14/
29) to 79% physical intervention trials (11/14). DMCs
were reported less frequently, from 23% in resources
and infrastructure trials (5/22) to 73% in pharmaceutical
intervention trials (97/132) or medical device trials (19/
26). Trials with neither committee most commonly in-
volved a complimentary intervention (3/6, 50%) or psy-
chological and behavioural (13/29, 45%). Further details
are provided in Tables 5 and 6.
Trial steering committees
Name
Trial Steering Committee was the most common TSC
name (61/144, 42%). Other variants were Steering
Committee (42/144, 29%); Steering Group (14/144, 10%)
and Executive Committee (10/144, 7%). Table 7 shows
other variations.
Membership
Four fifths indicated the number of committee members,
varying from half (BMJ, 3/6) to 85% (HTA, 71/84). The
number of members ranged from 2 to 52 with a median
of 7. Details are provided in Table 8.
One hundred and ten publications listed members
of which 84 specified a Chair. Other roles or fields of
expertise were detailed in almost half of trials with a
TSC (66/144). Common representation were clinical
(n = 46), statistical (n = 29) and patient and/or public
(PPI) (n = 39).
Reporting was unclear with regards to membership
and independence.
Journal manuscripts One publication specified that the
funder (NIHR) appointed the TSC, stating that members
were ‘researchers independent of the study funders, al-
though several have served on their advisory or funding
committees’. (BMJ12)
One publication indicated voting members when list-
ing members (Lancet25).
Ten NEJM publications gave details of TSC member-
ship beyond listing members and affiliations. Half of
these described sponsor representation, with one speci-
fying this representation as none voting (NEJM20).
All 32 (9 Lancet, 23 NEJM) supplements reporting
TSCs listed members and/or affiliations.
Thirteen NEJM protocols discussed committee
membership. Protocol reporting consisted listing
members by role and/or field of expertise (n = 10) or
by name (n = 6), of which three reported both.
Monographs Forty-six gave details of TSC membership
beyond listing members and affiliations.
Independence was discussed in 32 publications (32/
46, 69.6%), of which 30 specified an independent Chair.
Two reported funder input in selecting the Chair.
Members represented the following fields: clinical
(n = 12), PPI (n = 6), statistical (n = 3) and health
Fig. 1 Flowchart of identification of eligible papers
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Table 2 Trial demographics by journal
Journal (N in cohort) Total
(N = 264)BMJ (N = 16) NEJM (N = 55) Lancet (N = 66) HTA (N = 127)
n n/N% n n/N% n n/N% n n/N% n n/N%
Trial rationale Explanatory 0 0.0 0 0.0 5 7.6 2 1.6 7 2.7
Pragmatic 6 37.5 2 3.6 10 15.2 88 69.3 106 40.2
Not specified or clear 10 62.5 53 96.4 51 77.3 37 29.1 151 57.2
Funder origin Asia 0 0.0 1 1.8 3 4.5 0 0.0 4 1.5
Japan 0 0.0 1 1.8 2 3.0 0 0.0 3 1.1
South Korea 0 0.0 0 0.0 1 1.5 0 0.0 1 0.4
Australia 1 6.3 2 3.6 3 4.5 0 0.0 6 2.3
Australia 1 6.3 2 3.6 2 3.0 0 0.0 4 1.5
New Zealand 0 0.0 0 0.0 1 1.5 0 0.0 2 0.8
Europe 14 87.5 21 38.2 40 60.6 127 100.0 202 76.5
Belgium 0 0.0 1 1.8 0 0.0 0 0.0 1 0.4
Denmark 3 18.8 2 3.6 0 0.0 0 0.0 5 1.9
Finland 1 6.3 0 0.0 0 0.0 0 0.0 1 0.4
France 0 0.0 2 3.6 5 7.6 0 0.0 7 2.7
Germany 0 0.0 1 1.8 6 9.1 0 0.0 7 2.7
Ireland 1 6.3 0 0.0 2 3.0 0 0.0 3 1.1
Netherlands 2 12.5 1 1.8 2 3.0 0 0.0 5 1.9
Spain 0 0.0 0 0.0 1 1.5 0 0.0 1 0.4
Sweden 0 0.0 0 0.0 1 1.5 0 0.0 1 0.4
Switzerland 1 6.3 4 7.3 3 4.5 0 0.0 8 3.0
United Kingdom 6 37.5 9 16.4 19 28.8 127 100.0 161 61.0
Other (European Union) 0 0.0 1 1.8 1 1.5 0 0.0 2 0.8
North America 1 6.3 30 54.5 20 30.3 0 0.0 51 19.3
Canada 0 0.0 1 1.8 0 0.0 0 0.0 1 0.4
United States of America 1 6.3 29 52.7 20 30.3 0 0.0 50 18.9
Not specified 0 0.0 1 1.8 0 0.0 0 0.0 1 0.4
Recruitment setting Primary 4 25.0 2 3.6 5 7.6 46 36.2 57 21.6
Secondary only 2 12.5 2 3.6 5 7.6 17 13.4 26 9.8
Tertiary only 3 18.8 17 30.9 30 45.5 47 37.0 97 36.7
Secondary or tertiary (not specified) 0 0.0 0 0.0 2 3.0 3 2.4 5 1.9
Community 7 43.8 4 7.3 2 3.0 15 11.8 28a 10.6
Emergency 1 6.3 5 9.1 0 0.0 7 5.5 13 4.9
Hospice 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Social care 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Other setting 0 0.0 1 1.8 1 1.5 0 0.0 2b 0.8
Not clear 0 0.0 32 58.2 22 33.3 9 7.1 63c 23.9
Trial design Parallel 13 81.3 48 87.3 59 89.4 103 81.1 233 88.3
Sequential 0 0.0 1 1.8 1 1.5 1 0.8 3 1.1
Crossover 0 0.0 1 1.8 2 3.0 5 3.9 9 3.4
Cluster 2 12.5 0 0.0 2 3.0 11 8.7 15 5.7
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Table 2 Trial demographics by journal (Continued)
Journal (N in cohort) Total
(N = 264)BMJ (N = 16) NEJM (N = 55) Lancet (N = 66) HTA (N = 127)
n n/N% n n/N% n n/N% n n/N% n n/N%
Factorial 1 6.3 5 9.1 2 3.0 7 5.5 15 5.7
Number of trial arms 2 12 75.0 42 76.4 46 69.7 85 66.9 185 70.1
3 3 18.8 7 12.7 10 15.2 29 22.8 49 18.6
4 1 6.3 4 7.3 4 6.1 7 5.5 16 6.1
5 0 0.0 2 3.6 2 3.0 5 3.9 9 3.4
6 or more 0 0.0 0 0.0 4 6.1 1 0.8 5d 1.9
Type of intervention e, f Pharmaceutical 3 18.8 41 74.5 54 81.8 34 26.8 132 50.0
Cellular and gene
therapy
0 0.0 1 1.8 2 3.0 0 0.0 3 1.1
Medical device 0 0.0 5 9.1 5 7.6 16 12.6 26 9.8
Surgery 0 0.0 3 5.5 1 1.5 10 7.9 14 5.3
Radiotherapy 0 0.0 1 1.8 3 4.5 9 7.1 13 4.9
Psychological and
behavioural
6 37.5 0 0.0 1 1.5 22 17.3 29 11.0
Physical 2 12.5 2 3.6 0 0.0 10 7.9 14 5.3
Complimentary 0 0.0 0 0.0 1 1.5 5 3.9 6 2.3
Resources and
infrastructure
1 6.3 1 1.8 1 1.5 19 15.0 22 8.3
Other 4 25.0 2 3.6 1 1.5 12 9.4 19 7.2
Number of primary
outcomes
1 11 68.8 47 85.5 51 77.3 101 79.5 210 79.5
2 2 12.5 3 5.5 10 15.2 13 10.2 28 10.6
3 1 6.3 4 7.3 2 3.0 1 0.8 8 3.0
4 or more 2 12.5 1 1.8 2 3.0 11 8.7 16 6.1
Primary outcome type Subjective 1 primary outcome 3 18.8 0 0.0 2 3.0 39 30.7 44 16.7
2 + primary outcomes 1 6.3 0 0.0 0 0.0 4 3.1 5 1.9
Objective 1 primary outcome 6 37.5 46 83.6 46 69.7 53 41.7 151 57.2
2 + primary outcomes 3 18.8 6 10.9 13 19.7 6 4.7 28 10.6
Both 1 primary outcome 0 0.0 0 0.0 0 0.0 3 2.4 3g 1.1
2 + primary outcomes 1 6.3 2 3.6 1 1.5 14 11.0 18 6.8
Not clear 1 primary outcome 2 12.5 1 1.8 3 4.5 6 4.7 12 4.5
2 + primary outcomes 0 0.0 0 0.0 1 1.5 2 1.6 3 1.1
Allocation ratio Equal e.g. 1:1 13 81.3 46 83.6 55 83.3 115 90.6 229 86.7
Not equal e.g. 2:1 2 12.5 8 14.5 10 15.2 12 9.4 32 12.1
Not clear 1 6.3 1 1.8 1 1.5 0 0.0 3 1.1
Unit of randomisation Individual 12 75.0 52 94.5 62 93.9 113 89.0 239 90.5
GP practice 0 0.0 0 0.0 1 1.5 9 7.1 10 3.8
Dyad (e.g.
mother-child)
1 6.3 1 1.8 1 1.5 2 1.6 5 1.9
Other 3 18.8 2 3.6 2 3.0 3 2.4 10h 3.8
Blinding Yes, blinding 11 68.8 37 67.3 45 68.2 69 54.3 162 61.4
No, not blinded 2 12.5 3 5.5 5 7.6 33 26.0 43i 16.3
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economics (n = 1). Including the Chair, the number of
independents, discussed in 25 publications, ranged
from two to six (most commonly three, n = 17). Non-
independent members, discussed in three publications,
specified statistical (n = 3) and health economics (n = 2)
representation.
Thirty-one listed members without specifying inde-
pendence. Represented fields were Patient and Public
Involvement (PPI) (n = 21), clinical (n = 12), statistical
(n = 9), health economics (n = 3) and funder (n = 2).
Three allowed observers at meetings.
Meetings
Journal manuscripts One publication discussed meeting
frequency (bimonthly meetings (BMJ15)). One stated
yearly reports were circulated (Lancet3) possibly indicating
yearly meetings.
Seven supplementary protocols provided TSC meeting
information. Four gave the frequency of these, ranging
from monthly to annually. Two were unclear stating meet-
ings were held periodically. Others reported that meetings
held by teleconference (n = 2) and gave insight to report
contents (n = 1).
Monographs Twenty-five publications (25/144) dis-
cussed meeting frequency or timing. Timings, when
specified, were biyearly (n = 12); yearly (n = 7); quar-
terly (n = 2) and as required (n = 1). Three gave
meeting dates and another three gave the total num-
ber of meetings. One specified the length of TSC
meetings as 80–100 min. Four indicated timing of
Table 2 Trial demographics by journal (Continued)
Journal (N in cohort) Total
(N = 264)BMJ (N = 16) NEJM (N = 55) Lancet (N = 66) HTA (N = 127)
n n/N% n n/N% n n/N% n n/N% n n/N%
Justification
provided
Justification
not provided
1 6.3 9 16.4 15 22.7 10 7.9 35 13.3
Not clear 2 12.5 6 10.9 1 1.5 15 11.8 24 9.1
BMJ British Medical Journal, HTA Health Technology Assessment Monograph series, NEJM New England Journal of Medicine
aAdvertisements in newsletters (n = 1); Child and Adolescent Mental Health Services (n = 1); Community mental health teams (n = 1); Community nurse services
(n = 1); Community nursing services and community leg ulcers clinics (n = 1); Community old age psychiatry services (n = 1); Community sources (n = 1);
Department of Veterans Affairs (n = 3); National population registrar (n = 1); Community paediatricians (n = 1); Registrar (n = 3); Schools (n = 1); Secondary schools
(n = 1); University podiatry schools and podiatry clinics (n = 1); Vaccination centres in schools (n = 1); Villages (n = 1); Not specified (n = 8)
bOther setting: Veterans Affairs Medical Centre (n = 1); From other trials (n = 1)
cNot clear: Adult mental health setting (n = 1); Antenatal clinic (n = 1); Centres (n = 29); Child and Adolescent Mental Health Services (n = 1); Child Development
Centre (n = 1); Clinic site (n = 1); Clinical centres (n = 1); Clinical sites (n = 1), Clinics (n = 2); Countries (n = 2); European medical centres (n = 1); Institutes (n = 1);
Institutions (n = 1); Sites (n = 13); Not described (n = 7)
dTotal arms equal to: six (n = 2); eight (n = 1); nine (n = 1); twelve (n = 1)
eDefined by UK Clinical Research Collaboration Health Research Classification System
fCategories not mutually exclusive
gBoth: Composite (n = 3) (Disease improvement calculated from CHAQ, physician’ global assessment of disease activity, parents’ global assessment of overall well-
being, number of joints with limited range of movement (ROM), number of active joints and erythrocyte sedimentation rate (n = 1)); Foot and Ankle Outcome
Score (n = 1); Post-operative nausea and vomiting (n = 1)
hOther units of randomisation: Clinic (n = 1); Family (n = 2); Hospital (n = 1); Household (n = 1); Partner (n = 1); School (n = 1); Village (n = 1); Year group (n = 1);
Paediatric diabetes services (n = 1)
iJustification for no blinding: Not possible or practical due to nature of intervention or trial design (n = 30); Not possible/practical as in practice caused difficulties
for patients (n = 1); Not possible/practical as shown by other similar trials (n = 2); Not possible/practical so cluster randomisation approach used (n = 1); Not
possible – no additional justification given (n = 4); Attempted to blind although were not successful (n = 1); Large sample size means that results are not
compromise (n = 1); Not blinding reflects real practice (n = 2); Test for impact of not blinding post trial (n = 1)
Table 3 Material reviewed by type and journal
Material Journal (N in cohort) Total (N = 264)
BMJ (N = 16) NEJM (N = 55) Lancet (N = 66) HTA (N = 127)
n n/N% n n/N% n n/N% n n/N% n n/N%
Main trial publication 16 100.0 55 100.0 66 100.0 127 100.0 264 100.0
Study protocol as supplementary
material
0 0.0 50 90.9 0 0.0 NA - 50 18.9
Other supplementary material
excluding study protocol
5 31.3 52 94.5 50 75.8 NA - 107 40.5
BMJ British Medical Journal, HTA Health Technology Assessment Monograph series, NA not applicable, NEJM New England Journal of Medicine
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Table 4 Level of Trial Steering Committee (TSC) and Data Management Committee (DMC) reporting split by journal
Committee(s) reported Journal (N in cohort) Total
(N = 264)BMJ (N = 16) NEJM (N = 55) Lancet (N = 66) HTA (N = 127)
TSC and DMC reported 4 25.0% 31 56.4% 19 28.8% 55 43.3% 109 41.3%
N papers reporting TSC (N papers reporting DMC)
Acknowledged/listed 2 (2) 19 (23) 14 (15) 52 (50) 87 (90)
Main paper 2 (2) 7 (6) 5 (4) 3 (5) 17 (17)
Supplementary paper 0 (0) 0 (0) 0 (0) NA 0 (0)
Protocol 0 (0) 5 (2) 0 (0) NA 5 (2)
TSC only reported 2 12.5% 3 5.5% 1 1.5% 29 22.8% 35 13.3%
N papers reporting TSC
Acknowledged/listed 1 2 1 19 23
Main paper 1 1 0 10 12
Supplementary paper 0 0 0 NA 0
Protocol 0 0 0 NA 0
Reason for no DMC provided 0 0 0 3 3
DMC only reported 0 0.0% 17 30.9% 26 39.4 6 4.7% 49 18.6%
N papers reporting DMC
Acknowledged / listed 0 8 3 5 16
Main paper 0 6 22 1 29
Supplementary paper 0 1 1 NA 2
Protocol 0 2 0 NA 2
Reason for no TSC provided 0 0 0 0 0
Neither committee reported 10 62.5% 4 7.3% 20 30.3% 37 29.1% 71 26.9%
N papers
Reason for no TSC provided 0 0 0 0 0
Reason for no DMC provided 0 2 0 0 2
BMJ British Medical Journal, HTA Health Technology Assessment Monograph series, NA not applicable, NEJM New England Journal of Medicine
Table 5 Oversight committee split by intervention type
Intervention type TSC reported DMC reported
Yes No Yes No
N n n/N% n n/N% n n/N% n n/N%
Pharmaceutical 132 68 51.5% 64 48.5% 97 73.5% 35 26.5%
Cellular and gene therapy 3 0 0.0% 3 100.0% 2 66.7% 1 33.3%
Medical device 26 17 65.4% 9 34.6% 19 73.1% 7 26.9%
Surgery 14 9 64.3% 5 35.7% 9 64.3% 5 35.7%
Radiotherapy 13 7 53.8% 6 46.2% 5 38.5% 8 61.5%
Psychological and behavioural 29 14 48.3% 15 51.7% 11 37.9% 18 62.1%
Physical 14 11 78.6% 3 21.4% 8 57.1% 6 42.9%
Complimentary 6 3 50.0% 3 50.0% 2 33.3% 4 66.7%
Resources and infrastructure 22 13 59.1% 9 40.9% 5 22.7% 17 77.3%
Other 19 13 68.4% 6 31.6% 7 36.8% 12 63.2%
DMC Data Management Committee, TSC Trial Steering Committee
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first meeting as prior to (n = 2) or at (n = 1) trial
commencement and before recruitment (n = 1)
Role
Journal manuscripts Eleven Lancet and 17 NEJM publi-
cations indicated role or responsibility. No BMJ articles
discussed role. One supplementary appendix reporting
TSCs (1/23 NEJM) gave insight into TSC role.
Design and oversight
Four Lancet publications reported involvement in trial
design, specifically the committee designing the study with
sponsor (2/4), under surveillance of the DMC (1/4), or
supervising the design (1/4). Eleven NEJM publications re-
ported involvement in design, wherein the role encom-
passed overseeing (2/11), being responsible for (3/11) and/
or involvement in (7/11) trial design, with one specifying
that this was independent of the sponsor.
Three Lancet publications reported the TSC over-
see the trial, of which one stated that the TSC su-
pervised operations. Of the nine NEJM publications
discussing oversight and conduct, five stated that the
TSC oversees the trial (5/9), of which two required
that they oversee conduct specifically (2/9). A
Table 6 Oversight committee split by intervention type
Intervention type Committee(s) reported
TSC and DMC TSC and no DMC DMC and no TSC No TSC and no DMC
N n n/N% n n/N% n n/N% n n/N%
Pharmaceutical 132 60 45.5% 8 6.1% 37 28.0% 27 20.5%
Cellular and gene therapy 3 0 0.0% 0 0.0% 2 66.7% 1 33.3%
Medical device 26 16 61.5% 1 3.8% 3 11.5% 6 23.1%
Surgery 14 6 42.9% 3 21.4% 3 21.4% 2 14.3%
Radiotherapy 13 4 30.8% 3 23.1% 1 7.7% 5 38.5%
Psychological and behavioural 29 9 31.0% 5 17.2% 2 6.9% 13 44.8%
Physical 14 7 50.0% 4 28.6% 1 7.1% 2 14.3%
Complimentary 6 2 33.3% 1 16.7% 0 0.0% 3 50.0%
Resources and infrastructure 22 4 18.2% 9 40.9% 1 4.5% 8 36.4%
Other 19 7 36.8% 6 31.6% 0 0.0% 6 31.6%
DMC Data Management Committee, TSC Trial Steering Committee
Table 7 TSC name split by journal
Name of TSC Journal (N reporting TSC) Total
(N = 144)BMJ (N = 6) NEJM (N = 34) Lancet (N = 20) HTA (N = 84)
n n/N% n n/N% n n/N% n n/N% n n/N%
Trial Steering Committee 6 100.0 1 2.9 6 30.0 48 57.1 61 41.7
Steering Committee 0 0.0 18 52.9 12 60.0 12 14.3 42 29.2
Steering Group 0 0.0 0 0.0 0 0.0 14 16.7 14 9.7
Executive Committee 0 0.0 9 26.5 1 5.0 0 0.0 10 6.9
Trial Steering Group 0 0.0 0 0.0 0 0.0 4 4.9 4 2.8
Advisory Committee 0 0.0 2 5.9 0 0.0 0 0.0 2 1.4
Project Steering Group 0 0.0 0 0.0 0 0.0 2 2.4 2 1.4
Study Steering Committee 0 0.0 1 2.9 0 0.0 1 1.2 2 1.4
Clinical Research Organisation 0 0.0 1 2.9 0 0.0 0 0.0 1 0.7
External Protocol Advisory Committee 0 0.0 1 2.9 0 0.0 0 0.0 1 0.7
Monitoring and Steering Committee 0 0.0 1 2.9 0 0.0 0 0.0 1 0.7
Neurology Steering Committee 0 0.0 0 0.0 1 5.0 0 0.0 1 0.7
Scientific Advisory Group 0 0.0 0 0.0 0 0.0 1 1.2 1 0.7
Steering and Advisory Group 0 0.0 0 0.0 0 0.0 1 1.2 1 0.7
Trial Advisory Group 0 0.0 0 0.0 0 0.0 1 1.2 1 0.7
Note: Tabled sorted by total column. BMJ British Medical Journal, HTA Health Technology Assessment Monograph series, NEJM New England Journal of Medicine
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further four stated that the TSC was responsible for
study conduct (4/9).
One supplementary appendix reporting TSCs (1/32, 1/9
Lancet) indicated operational oversight role, specifically:
‘The Steering Committee was responsible for
overseeing the scientific and operational aspect of the
study’. (Lancet49)
Thirteen protocols discussed a role in oversight and
trial design: the role encompassed monitoring (n = 5)
and oversight of various aspects of the study (n = 5). The
TSC had a responsibility or participated in trial conduct
(n = 8) and design (n = 5). One stated that the TSC was
independent.
Decision-making
Two Lancet publications reported a decision-making
role, stating that the TSC could decide on study continu-
ation. While no NEJM main papers reported the decision-
making role, nine protocols did. Five explicitly defined the
TSC as the decision-making body, the remaining four
opted to provide examples of TSC decisions, such as alter-
ing sample size (n = 2), patient withdrawals (n = 1) and
trial stopping (n = 1).
Contribution to trial documentation, data and
analysis
Seven Lancet publications involvement in trial docu-
mentation, stating that the TSC wrote or contributed to
the final report (3/7), made the decision to publish (2/7),
or both (1/7). The TSC coordinated and resolved doubts
in interpretation in the protocol in another. Analysis and
data involvement was reported in five studies, three of
these stated the TSC had full access to data (3/5), one
supervised the analysis (1/5) and three interpreted the
results (one stating that this was done independently).
Another stated:
‘The (TSC) vouched for the completion and accuracy
of the data gathering and analysis’. (Lancet6)
Seven NEJM publications reported TSC involvement in
trial documentation, in contributing to writing the manu-
script (4/7) and developing the protocol (3/7), of which
one developed this with the sponsor. Four reported TSC
involvement in trial data, specifically the TSC had full ac-
cess to data (1/4) and was involved with data collection
(1/4); interpretation (1/4) and analysis (1/4). In seven, the
committee made the decision to publish, one stated that
the TSC vouches for integrity and completeness of the
data and six stated:
‘The (TSC) vouches for the accuracy and
completeness of the data and the analysis and the
fidelity of the study to the protocol’.
One supplementary appendix reporting TSCs (1/32,
1/23 NEJM) gave insight into role. Fifteen protocols
discussed TSC input into trial documentation, data
and analysis. The TSC was reported to have an input
in publications (n = 13), the protocol (n = 7) and side
studies (n = 4).
Communication
No publications specified communication between
TSC and other committees.
Table 8 Membership details provided split by journal
Journal (N reporting TSC) Total
(N = 144)BMJ (N = 6) NEJM (N = 34) Lancet (N = 20) HTA (N = 84)
Number of members n (n/N%) 3 (50.0) 20 (58.8) 16 (80.0) 71 (84.5) 110 (76.4)
mean (SD) 5 (2) 13 (12) 8 (5) 8 (6) 9 (7)
median (IQR) 5 (3) 9 (9) 6 (5) 6 (5) 7 (6)
(min, max) (4, 7) (4, 52) (3, 22) (2, 34) (2, 52)
Chair indicated n (n/N%) 3 (50.0) 20 (58.8) 9 (45.0) 52 (61.9) 84 (58.3)
Expertise of members indicated n (n/N %) 1 (16.7) 10 (29.4) 4 (20.0) 51 (60.7) 66 (45.8)
Expertise Chief investigator n (n/N%) 0 (0.0) 9 (26.5) 2 (10.0) 13 (15.5) 24 (16.7)
Trial coordinator n (n/N%) 0 (0.0) 1 (2.9) 0 (0.0) 5 (6.0) 6 (4.2)
Clinical expert n (n/N%) 0 (0.0) 3 (8.8) 2 (10.0) 41 (48.8) 46 (31.9)
Statistician n (n/N%) 0 (0.0) 4 (11.8) 2 (10.0) 23 (27.4) 29 (20.1)
PPI representative n (n/N%) 1 (16.7) 2 (5.9) 0 (0.0) 36 (42.9) 39 (27.1)
Health economist n (n/N%) 0 (0.0) 0 (0.0) 0 (0.0) 11 (13.1) 11 (7.6)
Sponsor representative n (n/N%) 0 (0.0) 5 (14.7) 1 (5.0) 2 (2.4) 8 (5.6)
Industry representative n (n/N%) 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.2) 2 (1.4)
BMJ British Medical Journal, HTA Health Technology Assessment Monograph series, IQR interquartile range, NEJM New England Journal of Medicine, PPI Patient
and Public Involvement, SD standard deviation, TSC Trial Steering Committee
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One appendix reporting TSCs (1/32) discussed com-
munication, stating:
‘(the DMC) made recommendations to the Steering
Committee regarding endpoint analysis or potential
safety concerns’. (Lancet49)
Eight protocols discussed the TSC communicating with
the DMC (n = 7) and a Critical Event Committee (n = 1).
Monograph Forty monographs described role.
Design and oversight
Twenty-seven monographs described an oversight role,
generally (11/27) or, more specifically, overseeing progress
towards interim and overall objectives (8/27) or study pro-
gress as a whole (8/27). Three stated independent over-
sight and two that his was on behalf of the sponsor.
Generic definitions of TSC monitoring were provided
in nine monographs. This was done in accordance
with the MRC guidelines (n = 6), Good Clinical
Practice (n = 1) and in two:
‘The (TSC) ensured that the rights, safety and well-
being of the trial participants were the most important
considerations and prevailed over the interests of
science and society’.
Decision-making
Role in decision-making was reported in seven mono-
graphs. Examples were about how the study is run (n = 2);
premature closing (n = 5); and how pilot data will inform
the main trial (n = 2).
Contribution to trial documentation, data and
analysis
Twelve had the TSC review trial specific documenta-
tion. Specifically, the statistical analysis plan (n = 8) and
protocol (n = 5).
Ten stated that the TSC review external information
and five had authority over the publication strategy. One
had the TSC approve further analysis and one approved
additional studies.
Communication
The committee received recommendations from the
DMC in six monographs, informed funders on trial pro-
gress in three, advised funders in one and liaised be-
tween the DMC and the Trial Management Group
(TMG) in another. One stated that TSC responsibility in
resolving disputes between PIs and another had the
DMC as a subgroup of the TSC.
Activities
Journal manuscripts TSC activity having impact on
trial design, conduct and analysis was reported in 12
publications (3 BMJ; 7 Lancet; 2 NEJM) with a total 14
examples reported (4 BMJ; 8 Lancet; 2 NEJM). No activ-
ities were reported in supplementary protocols.
Design
Twelve (12/14; 3/4 BMJ; 7/8 Lancet; 2/2 NEJM) publi-
cations reported TSC activity impacting trial design.
Reported activities varied within journal.
The BMJ reported TSC involvement changing the
sample size (n = 2) and primary outcome (n = 1):
‘Before the start of recruitment and data collection,
we changed the primary outcome to the reported quit
attempt measure, which is predictive of eventual
cessation. This followed expert advice from the Trial
Steering Committee on the basis of smoking cessation
research and approval from the Data Monitoring
Committee’. (BMJ15)
All seven Lancet decisions regarded early stopping.
In five, the TSC decided to stop recruitment, of
which three reported that this decision was based on
DMC recommendations. Others reported the TSC de-
ciding to close recruitment to a trial arm (n = 1) and
make the decision to continue recruitment following
an interim analysis (n = 1):
‘Without revealing any results, the DSMB
recommended to the Executive Committee and
sponsor that the trial continue to the original
pre-planned sample size. The basis for this
recommendation was that, because of the rapid
enrolment at the time of the interim analysis, there
was insufficient 90-day data to assess the secondary
endpoints, although there were no safety concerns.
The Executive Committee and sponsor accepted the
DSMB recommendation to continue enrolment, but
remained masked to all study results’. (Lancet36)
Within the NEJM publications reporting TSC activity
relating to trial design (n = 2), the committee established
when patients could have their dose tapered (NEJM42)
and when crossover could be permitted:
‘The independent Data and Safety Monitoring
Committee and Study Steering Committee
concluded that both progression-free survival and
overall survival were significantly longer in the
trametinib group than in the chemotherapy group
and that immediate crossover to trametinib should
be permitted’. (NEJM23)
One supplementary appendix reported TSCs (1/32)
publishing the letter of recommendation from the DMC
to the TSC requesting one arm be closed due to accruing
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safety data (NEJM38), this was consistent with the main
publication wherein the trial was prematurely stopped.
Conduct
No publication reporting TSC activity related to trial
conduct.
Analysis
Two (2/14; 1/4 BMJ; 1/8 Lancet) publications reported
TSC activity impacting analysis.
One described the TSC deciding to write a new SAP
(BMJ3) Another reported the TSC determining exclu-
sions from analysis and imputations for deaths or drop
outs (Lancet10).
Monographs Thirty-seven monographs reported 60 ex-
amples of TSC activity.
Design
Thirty-four examples of TSC activity impacting trial
design was reported in 23 monographs.
Activities included the TSC changing the entry criteria
(n = 7); endpoints or outcomes (n = 7); sample size (n = 2);
and randomisation ratio (n = 1). Another reported the
TSC closing a treatment arm (n = 1). Others reported
TSC impact in defining the study design (n = 6) and re-
cruitment period (n = 2).
Most significantly, the TSC made the decision to close
the trial in five studies, as in HTA238:
‘In a meeting of the Trial Steering Committee, it was
accepted that it would not be viable to proceed with
the trial and the formal procedure for closure
(including notification of MHRA and MREC) was
initiated in May 2005’. (HTA75)
One monograph discussed the TSC overriding the rec-
ommendations of the DMC to close the trial:
‘Although the DMC recommended continuation of
recruitment into FOOD following their meeting in
2002, the Steering Committee took the decision to
stop recruitment on 31 July 2003’. (HTA88)
Conduct
Fifteen examples of TSC activity impacting trial con-
duct was given in 14 monographs.
Examples of conduct were where the TSC: had input in
determining the data collection process (4/14); considered
consent issues (1/14) and input into safety issues; for ex-
ample, such as reviewing death data (1/14) and determin-
ing serious adverse event (SAE) data requirements (3/14).
In three (3/14) the TSCs made the decision to chan-
ging treatment regimens; for example:
‘The project Steering Group determined that (a
prescription) was inappropriate to a pragmatic study
of this kind. It was agreed that the outcome would be
more likely to represent the likely outcome of
introducing TUVP if staff were to manage patients
according to existing norms’. (HTA30)
Others (3/14) changed the recruitment procedure, for
example:
‘On reflection and discussion of these issues, the
research team and the Trial Steering Committee
members felt that some of these issues could have
been addressed (…). They concluded that many of the
problems encountered were a direct consequence of
the changes in research governance and ethical
procedures that prevent members of the research
team approaching patients directly, but instead place
the burden of recruiting patients on busy primary care
professionals’. (HTA75)
Analysis
Ten examples of TSC activity impacting analysis was
given in ten monographs.
The TSC impacted the analysis plan in seven mono-
graphs (7/10). Examples were: determining variables for
regression model (2/7), defining equivalence limits (1/7),
removing previously planned subgroup analyses (1/7),
deciding on the analysis approach to be used, e.g.
intention-to-treat (2/7) or suggesting additional analysis:
‘Finally, at the request of the TSC, a further
exploratory analysis to examine the interactive effect
of age on the effectiveness of MRI compared with no
MRI was conducted’. (HTA111)
Other activities were the TSC determining protocol vi-
olations (1/10) and making the decision to unblind the
trial team (2/10), for example:
‘The identification of treatments was established by code
break in the presence of the Chief Investigator, Trial
Statistician and Trial Coordinator on 20 March 2007 by
agreement with the TSC and DMEC’. (HTA104)
Discussion
The extent of the adoption of a TSC, the committee with
a majority of independent members to whom the DMC
make their recommendations, for trial oversight outside
of the UK is unknown. Within the UK the establishment
of a TSC is required by a number of major public fun-
ders yet, despite this, there is an absence of reporting
standards regarding their constitution, activities and im-
pact on trial conduct.
This paper aimed to provide the first review of report-
ing of TSC activity by reviewing published academic
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literature from within and outside the UK. Determining
the role and contribution of this executive oversight
committee was limited by a lack of reporting and, in par-
ticular, clear indication of whether this committee in-
cluded a majority of, or even any, independent members.
It was often unclear whether the TSC being referenced
was in fact the TSC or the TMG, the committee with
heavy intellectual and practical investment in governing
the day-to-day running of the trial. In trials where no
major decisions need to be made, this may seem un-
important. In trials where DMC recommendations are
not actioned then it is of increasing importance to
understand the extent of the vested interests of the
committee considering those recommendations. In the
cohort reported here one such example was noted
where the DMC recommended trial continuation but
the TSC decided to close the trial. Arguably, this may
be more concerning if this was the other way around;
however, poor reporting standards will obscure this
occurrence (HTA88).
When interpreting these results, it is important to
consider the limitations which include a restriction of
the cohort to the top medical journals and the NIHR
HTA Monograph series. While this has the advantage
publishing international trials, it may also be argued that
these are of higher quality. The poor standards observed
within this cohort, therefore, may be lower elsewhere.
The timeframe of this cohort also prevented consider-
ation of changes over time; however, given the absence
of attention received to this important role and its
reporting standards this is unlikely. As previously
discussed, the extent of the adoption of this oversight
committee structure is not known for trials outside of
UK and little is known about industry-funded and spon-
sored trials.
For TSCs to be accepted as good practice globally, it is
important that the benefits and impact of such a com-
mittee are reported. This paper has highlighted the need
to improve reporting of TSCs and, in particular, clarify
the independence, or otherwise, of its members. Despite
the academic literature search being conducted in 2012
there has been no advancement in reporting guidelines
in this area and the situation remains unchanged.
Current reporting recommendations for DMCs [1, 2]
could be used as a starting point with focus on decisions
made by the TSC.
One challenge of writing a report of a clinical trial is
including pertinent information within word limits set
by journals. It is often a balance of what can be left out
without jeopardising quality. However, clarity of report-
ing on decision-making processes would seem essential
given the potential for bias. With the availability of sup-
plementary material, researchers must make this infor-
mation publicly accessible. This would greatly aid the
transparency of clinical trials and allow understanding of
stakeholder involvement in decisions made.
Conclusions
This cohort examination provides the first examination
of reporting practice of Trial Steering Committee in-
volvement in randomised controlled trials. A lack of
reporting standards has been identified, resultantly un-
derstanding the benefits and impact of the TSC role
using the academic literature is challenging. Developing
reporting guidelines is essential to aid determining the
role and contribution of this executive oversight com-
mittee. This would improve reporting standards, which
would greatly aid the transparency of clinical trials and
allow understanding of stakeholder involvement in
decision-making.
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